LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cardiac Patients Given Less Blood During Transfusions Do Well

By LabMedica International staff writers
Posted on 24 Dec 2014
Image: Collecting blood for transfusion (Photo courtesy of Toby Melville).
Image: Collecting blood for transfusion (Photo courtesy of Toby Melville).
Blood transfusion might affect long-term mortality by changing immune function and thus potentially increasing the risk of subsequent infections and cancer recurrence.

Compared with a restrictive transfusion strategy, a more liberal strategy could reduce cardiac complications by lowering myocardial damage, thereby reducing future deaths from cardiovascular disease.

Clinicians at the Robert Wood Johnson Medical School (New Brunswick, NJ, USA) working with colleagues from several other institutions, recruited 2,016 patients from 47 hospitals across the USA and Canada. Patients aged 50 years and older with a hemoglobin concentration lower than 100 g/L within three days after undergoing surgery to repair a hip fracture, and a history of cardiovascular disease or risk factors for cardiovascular disease were enrolled in the randomized controlled trial. Half of the patients received larger quantities of transfused blood; and the other half received transfusions that were smaller by as much as two thirds.

The total population of 2,016 enrolled patients had a mean age of 81.6 years (range 5 to 103 years), 1,527 (76%) were women, and 1,268 (63%) had cardiovascular disease. The mean pre-transfusion hemoglobin concentration was 92 ± 5 g/L in the liberal transfusion strategy group and 79 ± 6 g/L in the restrictive transfusion strategy group. The number of units of red blood cells transfused post-randomization in the liberal transfusion strategy was 2.9-times larger than that in the restrictive transfusion strategy. Long-term mortality did not differ significantly between the two treatment groups as 432 (43.2%) of 999 patients died in the liberal transfusion strategy group and 409 (40.8%) of 1,003 died in the restrictive strategy group. The cause of death did not differ between the transfusion strategies and the proportion of deaths from cardiovascular disease, cancer, and infections were nearly identical in the two groups of the trial.

Jeffrey L. Carson, MD, a professor and lead author of the study said, “Physicians performing surgeries and other procedures judge whether blood is needed based on how much they have seen the patient lose and by closely watching vital signs such as blood pressure. If physicians overestimate and provide too much blood, the patient's circulatory system can be overloaded and breathing can be affected. The risk of infection can also increase. There are definite risks associated with transfusion. The classic ones are hepatitis and human immunodeficiency virus (HIV). They are as rare as being hit by lightning, but even so, why give more blood to anyone if you can't show it benefits them?” The study was published on December 9, 2014, in the journal the Lancet.

Related Links:

Robert Wood Johnson Medical School 


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more